Literature DB >> 21508694

Adjuvant treatment for early-stage endometrial cancer.

Israel Zighelboim1, Matthew A Powell.   

Abstract

A subgroup of endometrial cancer patients with early-stage disease will progress or eventually present with recurrent disease. Multiple risk stratification strategies have been attempted to direct adjuvant therapeutic interventions. Radiation has been the most common form of adjuvant therapy offered to these patients. Unfortunately, its use has not translated into survival improvements. There is growing evidence supporting the use of adjuvant chemotherapy and multimodal interventions for patients with endometrial cancer. This review focuses on the role of adjuvant therapies for patients with early-stage disease with emphasis on future directions for risk stratification and personalized treatment.

Entities:  

Mesh:

Year:  2011        PMID: 21508694     DOI: 10.1097/GRF.0b013e318218c5b8

Source DB:  PubMed          Journal:  Clin Obstet Gynecol        ISSN: 0009-9201            Impact factor:   2.190


  1 in total

1.  Mutational analysis of the tyrosine kinome in serous and clear cell endometrial cancer uncovers rare somatic mutations in TNK2 and DDR1.

Authors:  Meghan L Rudd; Hassan Mohamed; Jessica C Price; Andrea J O'Hara; Matthieu Le Gallo; Mary Ellen Urick; Pedro Cruz; Suiyuan Zhang; Nancy F Hansen; Andrew K Godwin; Dennis C Sgroi; Tyra G Wolfsberg; James C Mullikin; Maria J Merino; Daphne W Bell
Journal:  BMC Cancer       Date:  2014-11-26       Impact factor: 4.430

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.